Drug-Resistant Bacterial Infections and Alternative Therapies—2nd Edition

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Microbiology in Human Health and Disease".

Deadline for manuscript submissions: 30 September 2025 | Viewed by 474

Special Issue Editor


E-Mail Website
Guest Editor
Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY 14620, USA
Interests: antibiotic-resistance; bacterial infections; drug discovery; biofilms; alternative therapeutic agents; combinational therapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues

Antibiotic resistance has emerged as a global healthcare challenge, and therapeutic options for treating antibiotic-resistant infections are becoming scarce. Antibiotic resistance limits the effectiveness of existing antibiotics and complicates the treatment of infectious diseases. Addressing antibiotic resistance requires a multifaceted approach, and the development of novel alternatives to antibiotics is crucial to combat resistance. Such alternatives include the discovery/development of novel antibacterial agents, phages, enzybiotics, plant extracts, antibacterial nanoparticles, etc. These antibacterial agents may be beneficial in treating infections when used alone or in combination with available therapeutic options.

This Special Issue is focused on publishing primary research and review articles that explore novel therapeutic agents that could be used as alternatives to conventional antibiotics for managing drug-resistant bacterial infections. We welcome articles on topics including, but not limited to, the following:

  • Applications of phages as therapeutic agents and their synergy with antibiotics;
  • Applications of enzybiotics as therapeutic agents and their synergy with antibiotics;
  • Plant-based antibacterial agents;
  • Antibacterial nanoparticle- and alternative-agent-loaded delivery systems;
  • Drug discovery and the development of new antibacterial agents;
  • The treatment of biofilms and biofilm-associated infections with alternative agents.

Dr. Vijay Singh Gondil
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • alternative agents
  • antibiotics
  • phages
  • endolysins
  • phytochemicals
  • drug discovery
  • nanoparticles
  • biofilms

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

23 pages, 3549 KiB  
Article
Immunomodulatory Effects of Escherichia coli Phage GADS24 on Human Dendritic Cells
by Alia M. Aldahlawi, Ghadah A. Alsubhi, Jehan S. Alrahimi, Fatemah S. Basingab and Kawther A. Zaher
Biomedicines 2025, 13(7), 1519; https://doi.org/10.3390/biomedicines13071519 - 21 Jun 2025
Viewed by 285
Abstract
Background: Multidrug-resistant (MDR) Escherichia coli (E. coli) strains pose a significant public health challenge, which has led to the exploration of alternative therapeutic strategies. Due to their antibacterial and immunomodulatory properties, bacteriophages have emerged as promising therapeutic agents. Methods: This study [...] Read more.
Background: Multidrug-resistant (MDR) Escherichia coli (E. coli) strains pose a significant public health challenge, which has led to the exploration of alternative therapeutic strategies. Due to their antibacterial and immunomodulatory properties, bacteriophages have emerged as promising therapeutic agents. Methods: This study investigates the effects of GADS24, a novel lytic bacteriophage of E. coli, on human-monocyte-derived dendritic cells (DCs). DCs are exposed to purified GADS24 phage, bacterial lysate, or a combination of both. Flow cytometry was used to assess the expression of surface markers (HLA-DR, CD80, CD83, and CD86), and ELISA was used to measure cytokine production (IL-10 and IL-12p70). Results: Following treatment with bacterial lysate, a significant increase in DC maturation markers was observed. The GADS24 phage alone induced a moderate upregulation of these markers, decreased IL-10 secretion, and increased IL-12p70. Combining bacterial lysate and phage tempered the maturation response compared to the lysate treatment alone. Conclusion: These findings suggest that GADS24 exerts antibacterial activity and modulates host immunity by influencing DC maturation and cytokine production. Due to its dual antimicrobial and immunomodulatory functions, GADS24 is likely to be a valuable adjunctive therapy for multidrug-resistant (MDR) bacterial infections. Furthermore, in vivo studies are necessary to confirm these promising in vitro results. Full article
Show Figures

Figure 1

Back to TopTop